A recent report outlines the good and the bad news about asthma
Asthma is a common chronic condition among Australians, particularly children. In recent years, federal and state governments have responded to community and health professionals’ concerns by investing in strategies to improve asthma management.1 Coinciding with this, new pharmaceutical formulations have become available for managing asthma. The latest publication from the Australian Centre for Asthma Monitoring and the Australian Institute of Health and Welfare, Asthma in Australia 2005,2 provides a timely review of the good and the bad news about asthma over the past few years (Box).
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
The Australian Centre for Asthma Monitoring is a collaborating unit of the Australian Institute of Health and Welfare funded as part of the Australian Government’s initiative to establish and maintain the Australian Monitoring System for Asthma. The Woolcock Institute of Medical Research receives grants from GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim, and Guy Marks’s research group receives an allocation of this funding to support research studies in asthma and related diseases. Guy Marks has received unrestricted educational grants from GlaxoSmithKline and AstraZeneca to attend scientific meetings, and has undertaken contract research (data analysis) on behalf of GlaxoSmithKline.